Darya-Varia Executive and Leadership Team

Celso Lim, the Chief Financial Officer at Darya-Varia, directs all financial operations and strategic fiscal planning. Overseeing budgeting, forecasting, and financial reporting, the Chief Financial Officer ensures robust financial health across the organization. This leadership role involves managing capital allocation, optimizing investment strategies, and maintaining strong relationships with financial institutions. By analyzing market trends and economic indicators, Celso Lim drives financial performance and supports sustainable growth initiatives. The Chief Financial Officer's expertise is critical in navigating the complex financial landscape of the pharmaceutical manufacturing sector, ensuring compliance with regulatory requirements and maximizing shareholder value. Lim's strategic financial management underpins the company's ability to invest in research, development, and expansion, directly impacting Darya-Varia's long-term viability and market position.

Clinton Hess, the President & Commissioner at Darya-Varia, leads the strategic direction and governance of the company. This dual role encompasses executive leadership and board oversight, ensuring alignment between operational execution and long-term corporate objectives. The President & Commissioner directs key initiatives aimed at enhancing Darya-Varia's market presence and product portfolio, particularly in soft gelatin capsules, liquid preparations, and medicinal plasters produced at the Gunung Putri Plant. Hess's leadership ensures the effective implementation of the Integrated Management System across all facilities, maintaining ISO certifications and halal guarantees. By fostering collaboration between operational teams and the Board, Clinton Hess drives innovation and operational efficiency, supporting the mission of building a healthier Indonesia. This executive guides the company's growth trajectory and commitment to quality healthcare solutions.

Ian Kloer, the President & Director at Darya-Varia, spearheads the company's operational execution and strategic growth initiatives. This leadership position involves overseeing the production of sterile injection products and solid preparations at the Citeureup Plant, alongside managing the Toll Manufacturing business through PT Medifarma Laboratories. Kloer directs technology transfer, lab trials, and commercial production for both domestic and international markets, ensuring high-quality finished goods. The President & Director champions the company's commitment to quality and safety, evidenced by numerous ISO and SNI certifications, and the adherence to halal guarantee systems across all facilities. Ian Kloer's strategic oversight ensures Darya-Varia consistently meets market demands and upholds its mission of providing accessible, high-quality health facilities, driving progress for 45 years.

Sancoyo Antarikso, the Independent Commissioner at Darya-Varia, provides objective oversight and strategic guidance to the Board of Commissioners. This role involves critically evaluating management's proposals, ensuring adherence to corporate governance best practices, and safeguarding the interests of all stakeholders. The Independent Commissioner's responsibilities include reviewing financial statements, assessing business strategies, and advising on risk management frameworks. Antarikso's independent perspective is vital for maintaining transparency and accountability within the organization. By championing ethical conduct and sound business principles, Sancoyo Antarikso contributes to the long-term stability and integrity of Darya-Varia's operations. This position is crucial for fostering trust and confidence among investors, employees, and the wider community, reinforcing the company's commitment to excellence in healthcare provision.